Secondary transcriptomic analysis of 285 patients with resected stage IIIA-N2 NSCLC from the Lung ART trial: high tumour purity was associated with worse OS (48.5 vs 106.5 months) and DFS; an exploratory purity × postoperative radiotherapy interaction was seen for OS (P=.049).
RCTn = 285
Zrafi et al. Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial